Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. - Wikidata - awgldk - TriplyDB

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands.

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands.

http://www.wikidata.org/entity/Q37414620

about

A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases Cost-effectiveness of biological treatment of ulcerative colitis - a systematic review.Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease.A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review.

P2860

Q26775384-2CA65BB7-BA96-449D-96AF-FD53F57733C4 Q33871726-15738401-0CDB-4FA0-9674-CF9A66F26FA6 Q35069447-43D8FFA0-C7FE-47C1-A4EF-A36486390BFE Q36059239-63883376-6A4E-4569-B97B-D553AAF1CAF1 Q42369594-65BE962D-A29A-4D8E-8848-5773CCE60B8D Q47278775-A702588C-FC62-46D3-A545-F3672AA68375 Q51636964-E1BEF45E-9DFD-4139-A3FD-FFF12D5BF2C5 Q55690473-95273E22-71CF-4FFC-9268-C72B179EE06A

P2860

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands.

http://www.wikidata.org/entity/Q37414620

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 December 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost-Effectiveness of Inflixim ...... ve Colitis in the Netherlands.

@en

Cost-Effectiveness of Inflixim ...... ve Colitis in the Netherlands.

@nl

type

label

Cost-Effectiveness of Inflixim ...... ve Colitis in the Netherlands.

@en

Cost-Effectiveness of Inflixim ...... ve Colitis in the Netherlands.

@nl

prefLabel

Cost-Effectiveness of Inflixim ...... ve Colitis in the Netherlands.

@en

Cost-Effectiveness of Inflixim ...... ve Colitis in the Netherlands.

@nl

P1433

Q37414620-B17E1760-65AA-492D-96B5-FD2B940CD9D5

P1476

Q37414620-2F2F1DA5-D5E1-4885-A6F3-8A58DD3B5FA8

P2093

Q37414620-2BD79020-336C-407B-9E5B-481DC090C719

Q37414620-797EF50A-D17A-43AA-9890-B4A63DFB4AAC

P2860

Q37414620-0D14F7CC-9327-4ED3-B027-6F9F8F1FA84D

Q37414620-43EBE09B-F08B-46F3-A9CC-9415D57931A0

Q37414620-578A46C0-63CC-4734-ACF2-5E9E1BD411F2

Q37414620-5D7BE434-15C3-40D1-ABF2-C32DD29423C8

Q37414620-5F556678-852C-4031-AA10-BC1EDAF71352

Q37414620-70295808-CC7B-4346-A35F-EA798E46F4A6

Q37414620-8580F03F-05BB-43DD-87A9-7636422F6FC0

Q37414620-8E74595E-9A17-4158-BE8D-4E3AF015BC23

Q37414620-93F91A93-BE97-4CB5-955A-2EDBBBE2BEFE

Q37414620-9DD1C6AA-8CC7-4028-8C6D-E9E937600821

P2888

Q37414620-0E83B52F-A5CD-475C-A306-A1FE946A0584

P304

Q37414620-578DD61D-EAB9-4565-9A36-D185077C8B8F

P31

Q37414620-A82AADF1-9A25-41C4-ACF5-8974B612761B

P356

Q37414620-C1A30BD7-83A6-407B-9AF7-54E5FA989FD3

P478

Q37414620-4C45FD34-715F-4B1D-81F8-DC30FE27F223

P577

Q37414620-66BD77B0-FDAD-41E3-9191-517FD6C62DFB

P5875

Q37414620-9B0AD393-BB13-43C1-9655-93FB046EFC6B

P698

Q37414620-BD511CD5-D235-40A2-A32D-21D141C566E0

P921

Q37414620-4EBE6FD8-D466-46B8-A84F-1414667D4E5F

P932

Q37414620-1C151BD2-7EA1-4460-A64F-42C547ED5629

P356

S13554-012-0007-0

P1433

Biologics in Therapy

P1476

Cost-Effectiveness of Inflixim ...... ve Colitis in the Netherlands.

@en

P2093

Mohammad A Chaudhary

http://www.w3.org/2001/XMLSchema#string

Tao Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab for induction and maintenance therapy for ulcerative colitis

A simple clinical colitis activity index

Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?

European evidence-based Consensus on the management of ulcerative colitis: Current management.

Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Guidelines for the management of inflammatory bowel disease in adults.

Review article: monitoring of immunomodulators in inflammatory bowel disease.

Infliximab for the treatment of acute exacerbations of ulcerative colitis.

Ciclosporin for severe refractory colitis.

Modeling valuations for EuroQol health states

P2888

s13554-012-0007-0

P304

45-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13554-012-0007-0

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257804922

http://www.w3.org/2001/XMLSchema#string

P698

24392304

http://www.w3.org/2001/XMLSchema#string

P921

P932

3873082

http://www.w3.org/2001/XMLSchema#string